RheumatologyLive Editorial Staff

FDA decisions and ACR 2026 readouts spotlight PsA, lupus, Sjögren and GCA—new targeted therapies could reshape rheumatology care.

Oral TYK2 debut, EULAR head-to-head wins, lupus ALLEGORY surge, and new ACR guidance reshape rheumatology’s H1 2026.